References
- Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309–318.
- Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29.
- Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009;22(2):119–125.
- Hien TT, White NJ. Qinghaosu. Lancet. 1993;341(8845):603–608.
- Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985;228(4703):1049–1055.
- Medhi B, Patyar S, Rao RS, et al. Pharmacokinetic and toxicological profile of artemisinin compounds: an update. Pharmacology. 2009;84(6):323–332.
- Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its dervatives. Crit Rev Toxicol. 2010;40(5):405–421.
- Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev. 1996;60(2):301–315.
- Balint GA. Artemisinin and its derivatives: an important new class of antimalarial agents. Pharmacol Ther. 2001;90(2–3):261–265.
- Haynes RK, Ho WY, Chan HW, et al. Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. Angew Chem Int Ed Engl. 2004;43(11):1381–1385.
- Antonie T, Fisher N, Amewu R, et al. Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. J Antimcrob Chemother. 2014;69(7):1005–1006.
- Meshnick SR, Yang YZ, Lima V, et al. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother. 1993;37(5):1108–1114.
- Klonis N, Crespo-Ortiz MP, Bottova I. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci USA. 2011;108(28):11405–11410.
- Garah F B-E, Pitie M, Vendier L, et al. Alkylating ability of artemisinin after Cu(I)-induced activation. J Biol Inorg Chem. 2009;14(4):601–610.
- Li J, Zhou B. Biological actions of artemisinin: insights from medicinal chemistry studies. Molecules. 2010;15(3):1378–1397.
- Ding XC, Beck HP, Raso G. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol. 2011;27(2):73–81.
- Meunier B, Robert A. Heme as trigger and target for trioxane-containing antimalarial drugs. Acc Chem Res. 2010;43(11):1444–1451.
- Wang, J Zhang CJ, Chia WN, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nature Commun. 2015;6(1):1–11.
- Bhisutthibhan J, Pan XQ, Hossler PA, et al. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J Biol Chem. 1998;273(26):16192–16198.
- Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003;424(6951):957–961.
- O’neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin—the debate continues. Molecules. 2010;15(3):1705–1721. 10.3390/molecules15031705.
- Efferth T, Romero MR, Wolf DG, et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis. 2008;47(6):804–811.
- Uckun FM, Saund S, Windlass H, et al. Repurposing Anti-Malaria phytomedicine artemisinin as a COVID-19 drug. Front Phamacol. 2021;12:407.
- Galal AM, Ross SA, Jacob M, et al. Antifungal activity of artemisinin derivatives. J Nat Prod. 2005;68(8):1274–1276.
- Ho WE, Peh HY, Chan TK, et al. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther. 2014;142(1):126–139.
- Wu Y, Zeng Q, Qi Z, et al. Recent progresses in cancer nanotherapeutics design using atemisinins as free radical precursors. Front Chem. 2020;8:472.
- Lin L, Mao X, Sun Y, et al. Antibacterial mechanism of artemisinin/beta-cyclodextrins against methicillin-resistant Staphylococcus aureus (MRSA). Microb Pathog. 2018;118:66–73.
- Gopalakrishnan AM, Kumar N. Antimalarial action of artesunate involves DNA damage mediated by reactive oxygen species. Antimicrob Agents Chemother. 2015;59(1):317–325.
- Lee YJ, Jang HJ, Chung IY, et al. Drosophila melanogaster as a polymicrobial infection model for Pseudomonas aeruginosa and Staphylococcus aureus. J Microbiol. 2018;56(8):534–541.
- Park SY, Heo YJ, Kim KS, et al. Drosophila melanogaster is susceptible to Vibrio cholerae infection. Mol Cells. 2005;20(3):409–415.
- Kim BO, Jang HJ, Chung IY, et al. Nitrate respiration promotes polymyxin B resistance in Pseudomonas aeruginosa. Antioxid Redox Signal. 2021;34(6):442–451.
- Park S, Imlay JA. High levels of intracellular cysteine promote oxidative DNA damage by driving the Fenton reaction. J Bacteriol. 2003;185(6):1942–1950.
- Li W, Mo W, Shen D, et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet. 2005;1(3):e36.
- Jang HJ, Chung IY, Lim C, et al. Redirecting an anticancer to an antibacterial hit against methicillin-resistant Staphylococcus aureus. Front Microbiol. 2019;10:350.
- Avery MA, Muraleedharan KM, Desai PV, et al. Structure-activity relationships of the antimalarial agent artemisinin. 8. design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria. J Med Chem. 2003;46(20):4244–4258.
- Hassett DJ, Alsabbagh E, Parvatiyar K, et al. A protease-resistant catalase, KatA, released upon cell lysis during stationary phase is essential for aerobic survival of a Pseudomonas aeruginosa oxyR mutant at low cell densities. J Bacteriol. 2000;182(16):4557–4563.
- Zimmermann A, Reimmann C, Galimand M, et al. Anaerobic growth and cyanide synthesis of Pseudomonas aeruginosa depend on anr, a regulatory gene homologous with fnr of Escherichia coli. Mol Microbiol. 1991;5(6):1483–1490.
- Shin DH, Choi YS, Cho YH. Unusual properties of catalase A (KatA) of Pseudomonas aeruginosa PA14 are associated with its biofilm peroxide resistance. J Bacteriol. 2008;190(8):2663–2670.
- Hong Y, Zeng J, Wang X, et al. Post-stress bacterial cell death mediated by reactive oxygen species. Proc Natl Acad Sci USA. 2019;116(20):10064–10071.
- Valko M, Morris H, Cronin M. Metals, toxicity and oxidative stress. Curr Med Chem. 2005;12(10):1161–1208. 10.2174/0929867053764635.
- Kim SY, Park C, Jang HJ, et al. Antibacterial strategies inspired by the oxidative stress and response networks. J Microbiol. 2019;57(3):203–212.
- Beswick PH, Hall GH, Hook AJ, et al. Copper toxicity: evidence for the conversion of cupric to cuprous copper in vivo under anaerobic conditions. Chem Biol Interact. 1976;14(3–4):347–356.
- Liu Y, Li R, Xiao X, et al. Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria. Crit Rev Microbiol. 2019;45(3):301–314.
- Denoyer D, Pearson HB, Clatworthy SA, et al. Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution. Oncotarget. 2016;7(24):37064–37080. 10.18632/oncotarget.9245.
- He Z, Chen L, You J, et al. In vitro interactions between antiretroviral protease inhibitors and artemisinin endoperoxides against Plasmodium falciparum. Int J Antimicrob Agents. 2010;35(2):191–193.
- White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother. 2013;57(12):5792–5807.
- Finney LA, O’Halloran TV. Transition metal speciation in the cell: insights from the chemistry of metal ion receptors. Science. 2003;300(5621):931–936.
- Bhagi-Damodaran A, Petrik I, Lu Y. Using biosynthetic models of heme-copper oxidase and nitric oxide reductase in myoglobin to elucidate structural features responsible for enzymatic activities. Isr J Chem. 2016;56:773–790.
- Georgopoulos PG, Roy A, Yonone-Lioy MJ, et al. Environmental copper: its dynamics and human exposure issues. J Toxicol Env Heal B. 2001;4(4):341–394.
- Bondarczuk K, Piotrowska-Seget Z. Molecular basis of active copper resistance mechanisms in Gram-negative bacteria. Cell Biol Toxicol. 2013;29(6):397–405.
- Gunjan S, Sharma T, Yadav K, et al. Artemisinin derivatives and synthetic trioxane trigger apoptotic cell death in asexual stages of Plasmodium. Front Cell Infect Microbiol. 2018;8:256.
- Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23(8):917.
- Suresh N, Haldar K. Mechanisms of artemisinin resistance in Plasmodium falciparum malaria. Curr Opin Pharmacol. 2018;42:46–54.
- Gaetke LM, Chow CK. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology. 2003;189(1–2):147–163.
- Szymański P, Frączek T, Markowicz M, et al. Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals. 2012;25(6):1089–1112.